SAN DIEGO--(BUSINESS WIRE)--Youngevity International, Inc. (OTCQX: YGYI) (www.YGYI.com), a global direct marketer of nutritional and lifestyle products and also a vertically-integrated producer of gourmet coffees for the commercial, retail and direct sales channels, announced today the successful completion of its pilot study conducted at the Richardson Center for Functional Foods and Nutraceuticals (“RCFFN”) at the University of Manitoba.
The RCFFN is one of the most advanced bioprocessing and product development facilities in Canada and around the world. The RCFFN has focused on value-added foods, food bioactives, and nutraceuticals that offer health promotion, performance enhancement, and disease prevention and management since 2006.
The pilot study was performed as the initial phase to the comprehensive and detailed study the RCFFN is conducting on the signature “90 For Life” Youngevity product set and their effects on various health biomarkers, which include those for weight management, inflammation, and blood sugar issues. The Ethics Committee at the University of Manitoba reviewed and approved the Youngevity products and their dosage levels in the rigorous protocols that will be used for the study. It was deemed that the Youngevity products chosen were highly tolerable and well within the range of the confidence levels to initiate the comprehensive study.
Dr. Ramprasath Vanu Ramkumar, Adjunct Professor and Research Associate for the Department of Human Nutritional Sciences at RCFFN, said, “The Youngevity research protocols are comprehensive and rigorous. We are very pleased that the initial pilot program was a success and brings us confidence that the larger scale study should run smoothly and provide promising results.”
“The successful completion of the pilot study is another milestone for Youngevity, and we expect the research will be completed by the first quarter of 2014 and will be reported within the same time frame,” said Steve Wallach, Youngevity’s Chief Executive Officer. “This is Youngevity’s second large scale research study performed by a recognized academic research institution to provide the best analysis of these signature Youngevity products. In the past year, the Nutraceutical Research Institute at Clemson University directed a research study demonstrating the safety, inflammatory benefits, and effect on various human cancer cells lines of the Youngevity products, Beyond Tangy Tangerine® and Ultimate Classic Plant Derived Minerals.”
About Youngevity International Inc.
Youngevity International Inc., (OTCQX: YGYI) (www.YGYI.com) is a fast-growing, innovative, multi-dimensional company that offers a wide range of consumer products and services, primarily through person-to-person selling relationships that comprise a “network of networks.” The Company also is a vertically-integrated producer of the finest coffees for the commercial, retail and direct sales channels. The Company was formed after the merger of Youngevity Essential Life Sciences (www.youngevity.com) and Javalution Coffee Company in the summer of 2011. The company was formerly known as AL International, Inc. and changed its name to Youngevity International Inc. in July 2013.
Safe Harbor Statement
This release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. The forward-looking statements contained in this press release include statements regarding the results anticipated from the study at RCFFN and the Company’s expected future growth. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.